Meda Rejects Sweetened Mylan Bid

Swedish specialty pharmaceuticals company Meda rejected a sweetened merger bid from U.S. peer Mylan, saying it prefers to remain a stand-alone company, while a lack of support from its largest shareholder would scuttle the deal anyway.



from WSJ.com: US Business http://ift.tt/1rDxykm

via IFTTT